Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone...

Full description

Bibliographic Details
Main Authors:	Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Arias
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2020-02-01
Series:	Drugs - Real World Outcomes
Online Access:	https://doi.org/10.1007/s40801-020-00184-w

id	doaj-9f66259fcf7f4a05aff9951c1044b712
record_format	Article
spelling	doaj-9f66259fcf7f4a05aff9951c1044b7122021-03-11T11:27:40ZengAdis, Springer HealthcareDrugs - Real World Outcomes2199-11542198-97882020-02-0171858510.1007/s40801-020-00184-wCorrection to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational StudyNestor Szerman0Ignacio Basurte-Villamor1Pablo Vega2Jose Martinez-Raga3Carlos Parro-Torres4Julia Cambra Almerge5Lara Grau-López6Mario De Matteis7Francisco Arias8Instituto Psiquiatría y Salud Mental, Hospital General Universitario Gregorio MarañónInstituto Psiquiatría y Salud Mental, Hospital General Universitario Gregorio MarañónInstituto de AdiccionesPsychiatry Department, University Hospital Dr. Peset, University of Valencia and University CEU-UCHPsychiatry Department, Hospital General Universitario Gregorio MarañónPsychiatry Department, “Proyecto Hombre”Addiction and Dual Diagnosis Unit, Department of Psychiatry, Vall d’Hebron University Hospital, CIBERSAMPsychiatry Department, Hospital General Universitario Gregorio MarañónPsychiatry Department, 12 de Octubre University HospitalA randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone [29].https://doi.org/10.1007/s40801-020-00184-w
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Nestor Szerman Ignacio Basurte-Villamor Pablo Vega Jose Martinez-Raga Carlos Parro-Torres Julia Cambra Almerge Lara Grau-López Mario De Matteis Francisco Arias
spellingShingle	Nestor Szerman Ignacio Basurte-Villamor Pablo Vega Jose Martinez-Raga Carlos Parro-Torres Julia Cambra Almerge Lara Grau-López Mario De Matteis Francisco Arias Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study Drugs - Real World Outcomes
author_facet	Nestor Szerman Ignacio Basurte-Villamor Pablo Vega Jose Martinez-Raga Carlos Parro-Torres Julia Cambra Almerge Lara Grau-López Mario De Matteis Francisco Arias
author_sort	Nestor Szerman
title	Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
title_short	Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
title_full	Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
title_fullStr	Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
title_full_unstemmed	Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
title_sort	correction to: once‑monthly long‑acting injectable aripiprazole for the treatment of patients with schizophrenia and co‑occurring substance use disorders: a multicentre, observational study
publisher	Adis, Springer Healthcare
series	Drugs - Real World Outcomes
issn	2199-1154 2198-9788
publishDate	2020-02-01
description	A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone [29].
url	https://doi.org/10.1007/s40801-020-00184-w
work_keys_str_mv	AT nestorszerman correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT ignaciobasurtevillamor correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT pablovega correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT josemartinezraga correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT carlosparrotorres correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT juliacambraalmerge correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT laragraulopez correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT mariodematteis correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy AT franciscoarias correctiontooncemonthlylongactinginjectablearipiprazoleforthetreatmentofpatientswithschizophreniaandcooccurringsubstanceusedisordersamulticentreobservationalstudy
_version_	1724225519782723584

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

Similar Items